Effects of Fatty Acids on Hematological Neoplasms: A Mini Review.


Journal

Nutrition and cancer
ISSN: 1532-7914
Titre abrégé: Nutr Cancer
Pays: United States
ID NLM: 7905040

Informations de publication

Date de publication:
2022
Historique:
pubmed: 7 8 2021
medline: 14 5 2022
entrez: 6 8 2021
Statut: ppublish

Résumé

Hematological neoplasias are the fourth cause of death in the world. All of them are responsible of bad quality of life, due to heavy therapies administration and a lot of side effects correlated to. It arises a new concept of "multitherapy", in which fatty acids availment is used to contrast and reduce toxic effects and ameliorate chemotherapeutic agents asset. In Vitro studies have confirmed that fatty acids, in particular ω-3 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are able to help canonical therapies to contrast cancer cell expansion and proliferation. In clinical trials it is also almost clear that fatty acids are useful to build new personalized therapies for a better condition of life. In this review we have summarized most recent studies on cancer cell lines and clinical trials on patients with fatty acids supplementation in diet therapies. We have found that fatty acids could be useful to contrast side effects during chemotherapeutic drugs therapies; they are also able to block cancer cell metabolic pathways for proliferation and contrast adverse effects, even when they are used in combination with traditional therapies or innovative, like monoclonal antibodies or CAR-T therapy. These aspects are crucial for better health condition of patients.

Identifiants

pubmed: 34355630
doi: 10.1080/01635581.2021.1960389
doi:

Substances chimiques

Fatty Acids 0
Fatty Acids, Omega-3 0
Docosahexaenoic Acids 25167-62-8
Eicosapentaenoic Acid AAN7QOV9EA

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1538-1548

Auteurs

Silvia Giannattasio (S)

School of Specialization in Food Sciences, University of Rome Tor Vergata, Rome, Italy.

Maria Dri (M)

Doctoral School of Applied Medical and Surgical Sciences, University of Rome Tor Vergata, Rome, Italy.

Giuseppe Merra (G)

Section of Clinical Nutrition and Nutrigenomics, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.

Giovanna Caparello (G)

School of Specialization in Food Sciences, University of Rome Tor Vergata, Rome, Italy.

Tiziana Rampello (T)

School of Specialization in Food Sciences, University of Rome Tor Vergata, Rome, Italy.

Laura Di Renzo (L)

Section of Clinical Nutrition and Nutrigenomics, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH